# Verici Dx offers three-test platform for kidney transplant risk assessment

- Link: https://www.directorstalkinterviews.com/verici-dx-offers-three-test-platform-for-kidney-transplant-risk-assessment/4121262752
- Published: 2026-09-17T10:31:00+01:00
- Author: Amilia Stone

[Verici Dx](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)
has built a three-product kidney transplant diagnostics portfolio designed to assess
patient risk before transplantation and monitor major complications after surgery.

The portfolio consists of Clarava, Tutivia and Protega, with each test addressing
a different stage of kidney transplant care. Clarava assesses the risk of acute 
rejection before transplantation, Tutivia identifies acute rejection risk after 
transplantation, and Protega assesses the risk of progressive fibrosis in the transplanted
kidney.

Together, the products give Verici Dx coverage across several important stages of
the transplant pathway rather than focusing on a single complication or point in
patient care.

Clarava is the earliest-stage test in that pathway. It uses an RNA gene signature
to help determine an individual patient’s risk of acute rejection during pre-transplant
assessment.

Current approaches to assessing rejection risk before transplantation can use broad
factors such as recipient age, retransplantation, race and the presence of antibodies
against common donors. Clarava adds a patient-specific molecular assessment that
could help clinicians determine the appropriate level of immunosuppression more 
precisely.

The test is designed for patients who have already been listed for a kidney transplant
and provides information before surgery takes place. This gives Verici Dx a role
at the pre-transplant stage, where treatment planning and risk assessment begin.

Following transplantation, Tutivia addresses the risk of acute rejection.

Tutivia is a blood-based test that uses a transcriptomic RNA expression signature
and a proprietary artificial intelligence algorithm to produce an acute rejection
risk score from zero to 100. A predetermined cut-off of 50 separates patients into
lower and higher risk categories.

The test was evaluated in a prospective, blinded international validation study 
involving 151 kidney transplant patients across 13 transplant centres in five countries.
Blood was collected at the time of protocol or for-cause biopsies during the first
six months after transplantation.

Among the 151 patients, 46 rejection events were identified according to BANFF 2019
criteria, including borderline T-cell mediated rejection. Patients receiving a high-
risk Tutivia result had a 5.74 times higher hazard of acute rejection than those
receiving a low-risk result.

Tutivia also identified acute rejection from as early as six days after surgery 
and showed 83% sensitivity, identifying 20 of 24 cases where a for-cause biopsy 
was performed within 60 days of transplant. This early assessment is central to 
the product’s role. RNA signatures can provide information from the first week following
transplantation without relying on injury markers that may be affected by the surgery
itself.

Protega extends Verici Dx’s post-transplant offering beyond acute rejection and 
into the risk of progressive fibrosis.

Fibrosis involves progressive scarring in the transplanted kidney and is primarily
assessed through histological analysis of kidney biopsies. Protega provides an additional
blood-based measure of the likelihood that fibrosis will develop or progress.

The prognostic assay analyses multiple RNA biomarkers from peripheral blood following
kidney transplantation and produces a risk score between zero and 100. A clinically
validated cut-off classifies recipients as being at either lower or higher risk 
of developing progressive fibrosis under BANFF 2019 criteria.

The three-product structure gives Verici Dx coverage across several clinical decision
points within the same patient pathway. Clarava addresses risk before surgery, Tutivia
addresses acute rejection after transplantation, and Protega addresses the risk 
of progressive tissue damage.

_**[Verici Dx Plc](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)**(
LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests
forming a kidney transplant diagnostics platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient outcomes._

Share on:
